QGEN · Qiagen N.V.

Track QGEN — free

$44.92 +0.42 (+0.93%) At close · Aug 20

Market Cap

$9.24B

206.50M

Up next

Next earnings call

Nov 10, 2026 Est · unconfirmed · in 12 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Buy Momentum Weak Sentiment Bearish Fundamentals Excellent Quant / Vol High

Market backdrop VIX 14.9 · calm Equity put/call 0.52

Technical

price trend

Buy

50 / 200-day cross No cross

Price vs 200-day avg +4%

above

Price vs 50-day avg +10%

above

RSI (14) 66

neutral

MACD trend Positive

52-week position 52%

mid-range

Momentum

relative strength

Weak

1-month return +10%

trailing

6-month return −9%

trailing

YTD return −1%

this year

Relative strength −21%

vs S&P · 6-mo

Sentiment

smart money

Bearish

Trend (MA cross) No cross

50d $40 › 200d $43 — 200d above 50d

Institutional flow Distributing

-5% holders QoQ · +67 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

3.99% of float · ▲ +3.8% MoM · 4.0 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

335 holders — mid 3-yr range

Squeeze score 60

elevated · 0–100

Fundamentals

Excellent

Revenue growth +6%

Y/Y

Gross margin 62%

expanding

EPS growth +424%

Y/Y

Free cash flow $453.3M

Buyback $100.0M

authorized

Balance sheet $815.4M

net debt

Quant / Vol

risk profile

High

Volatility 34%

annualized · 1-yr

Max drawdown −41%

past year

ATR 2.6%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Beat or met 1 of last 3

Latest guidance · from the Earnings Call filed Jun 30, 2026

full year

Total net sales growth 1% – 2%

Adjusted diluted EPS $2.43

third quarter

Total net sales growth 1% – 2%

Adjusted diluted EPS $0.62

Prior guidance period ended · from the Earnings Call filed Sep 30, 2025

Adjusted EPS · 2025 $2.38

Net sales growth · 2025 4% – 5%

Core portfolio sales growth · 2025 5% – 6%

Guided vs delivered · last 3 settled

Net sales 2023

guided at least $1.97B

guided at least $1.97B $1.97B Miss −0.2%

Adjusted EPS 2023

guided at least $2.07

guided at least $2.07 $1.48 Miss −28.5%

Impact on EPS next year

guided $0.02 – $0.03

guided $0.02 – $0.03 $0.37 Beat +1380.0%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy

0 · 3 · 3

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+4% Bullish

Price vs 50-day avg

+10% Bullish

RSI (14)

66 Neutral

MACD trend

Positive Bullish

52-week position

52% Neutral

Market signals — smart money & positioning

Bearish · 2 of 6

Trend (MA cross) No cross

50d $40 › 200d $43 — 200d above 50d

Institutional flow Distributing

-5% holders QoQ · +67 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

3.99% of float · ▲ +3.8% MoM · 4.0 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

335 holders — mid 3-yr range

Price context

position in its 52-week range

Range low $33 Now $45 · 52% Range high $56

vs 200-day avg +4% vs 50-day avg +10%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Diagnostics & Research — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
QGEN Qiagen N.V. this stock	$9.24B	-1.0%	+5.7%	—	4.0%
TMO Thermo Fisher Scientific Inc.	$231.21B	+5.9%	+14.5%	33.6	1.3%
DHR Danaher Corp /De/	$147.41B	-5.7%	+8.5%	37.2	1.7%
NTRA Natera, Inc.	$46.86B	+41.9%	-2.8%	—	3.0%
IDXX Idexx Laboratories Inc /De	$44.29B	-16.9%	+10.4%	39.5	2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

335

% held: 72.3%
Net QoQ: +17.0M sh
Top holder: WELLINGTON MANAGEMENT GRO…

Held Float

View

Held by Funds

Fund positions

104

View

Short & Settlement

Short Interest Rising

Shares short

8.2M

Days to cover: 4.0d
Change: +303.5K sh

View

Short Volume

Short vol %

41%

As of: Aug 20, 2026

Short Total

View

Fails to Deliver

FTD shares

Value: $2.2K
As of: Jul 17, 2026

View

Off-Exchange

Off-exchange %

37.8%

Week of: Jul 13, 2026

Off-exch Lit

View

Smart Money

Congressional Trades Sell

Member

Peter Welch

Amount: $1.0K–$15.0K
Traded: Mar 24, 2020

View

Financials

Revenue (FY)

$2.1B

Net income (FY): $424.9M
EPS diluted: $1.94

View

Buybacks

Authorized

$100.0M

View

Filings

SEC Filings

Latest

6-K

Filed: Aug 7, 2026
This year: 10

View

Proposed Sales

Value

$1.5M

Shares: 31.4K
Filed: Aug 15, 2025

View

Earnings & Events

Earnings Calls Upcoming

Next call

Sep 14, 2026

Last call: Aug 6, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
QGEN	+3.5%	+9.7%	-9.3%	+7.5%	-1.1%
SPY	-0.4%	+2.9%	+11.6%	+3.0%	+12.8%
vs SPY	+3.9%	+6.8%	-20.9%	+4.5%	-13.8%

Capital returns

Latest dividend

$0.35 / share · ex Jul 7, 2026

Raised 40%

Paid (TTM)

$0.35 / share · 1 payout

Dividend yield (TTM, derived)

— · history filling in

Buyback program · as of Jul 12, 2021

Authorized

$100.00M

Spent (derived)

—

Remaining

—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1015820 CUSIP N72482156 13F (30d) 329 filings 303 filers Visit website Investor relations

QGEN · Qiagen N.V.

Price & Indicators

Up next

Equibles Rating

Guidance & track record

Technicals

Versus peers

At a glance

Performance

Capital returns